Acute: Inhalation of the drug in doses in excess of those recommended may lead to temporary suppression of adrenal function. This does not require emergency action. In these patients treatment with Rinoclenil diproprionate by inhalation should be continued at a dose sufficient to control asthma; adrenal function recovers in a few days and can be verified by measuring plasma cortisol.
Chronic: Use of inhaled Rinoclenil dipropionate in daily doses in excess of 1,500 micrograms over prolonged periods may lead to some degree of adrenal suppression. Monitoring of adrenal reserve may be indicated. Treatment should be continued at a dose sufficient to control asthma.
Special care is necessary in patients with active or quiescent pulmonary tuberculosis.
None
Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common ( 1/10), common ( 1/100 and <1/10), uncommon ( 1/1000 and <1/100), rare ( 1/10,000 and <1/1000), very rare (<1/10,000) including isolated reports and not known (cannot be estimated from the available data). Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo and comparator group has not been taken into account in estimation of these frequencies. Rare and very rare events were generally determined from spontaneous data.
| System Organ Class | Adverse Event | Frequency |
| Infections & Infestations | Candidiasis of the mouth and throat. | Very Common |
| Immune System Disorders | Hypersensitivity reactions with the following manifestations: | |
| Rashes, urticaria, pruritis, erythema. | Uncommon | |
| Oedema of the eyes, face, lips and throat | Very Rare | |
| Respiratory symptoms (dyspnoea and/or bronchospasm) | Very Rare | |
| Anaphylactoid/anaphylactic reactions | Very Rare | |
| Endocrine Disorders | Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma | Very Rare |
| Psychiatric Disorders | Psychomotor hyperactivity, sleep disorders, anxiety, depression, aggression, behavioural changes (predominantly in children) | Not known |
| Respiratory, Thoracic & Mediastinal Disorders | Hoarseness/throat irritation, cough | Common |
| Paradoxical bronchospasm | Very Rare | |
| Eosinophilic pneumonia | Not Known | |
| Skin and subcutaneous tissue disorders | Easy bruising, skin thinning | Not known |
Candidiasis of the mouth and throat (thrush) occurs in some patients, the incidence increasing with doses greater than 400 micrograms of Rinoclenil dipropionate per day. Patients with high blood levels of Candida precipitins, indicating a previous infection, are most likely to develop this complication. Patients may find it helpful to rinse their mouth thoroughly with water after using the inhaler. Symptomatic candidiasis can be treated with topical anti-fungal therapy whilst still continuing with Easyhaler® Rinoclenil 200 micrograms/dose treatment.
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma (see 4.4 Special Warnings and Precautions for Use).
In some patients inhaled Rinoclenil dipropionate may cause hoarseness, cough, throat irritation and sore throat. It may be helpful to rinse the mouth out with water immediately after inhalation.
As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. The Rinoclenil dipropionate preparation should be discontinued immediately, the patient assessed, and if necessary alternative therapy instituted.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
No clinically relevant findings were observed in preclinical studies.
Rinoclenil dipropionate given by inhalation offers preventative treatment for asthma. It provides effective anti-inflammatory action in the lungs with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically. It also offers preventive treatment of asthma.
Easyhaler® Rinoclenil 200 micrograms/dose is indicated in the following:
Adults Prophylactic management in:
Mild asthma (PEF values greater than 80% predicted at baseline with less than 20% variability):
Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular basis.
Moderate asthma (PEF values 60-80% predicted at baseline with 20-30% variability):
Patients requiring regular asthma medication and patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone.
Severe asthma (PEF values less than 60% predicted at baseline with greater than 30% variability):
Patients with severe chronic asthma. On transfer to high dose inhaled Rinoclenil dipropionate, many patients who are dependent on systemic corticosteroids for adequate control of symptoms may be able to reduce significantly or eliminate their requirement for oral corticosteroids.
Rinoclenil dipropionate (BDP) is a pro-drug with weak glucocorticoid receptor binding activity. It is hydrolysed via esterase enzymes to the active metabolite Rinoclenil-17-monopropionate (B-17-MP), which has high topical anti-inflammatory activity.
Absorption
When administered via inhalation (via metered dose inhaler) there is extensive conversion of BDP to the active metabolite B-17-MP within the lungs prior to systemic absorption. The systemic absorption of B-17-MP arises from both lung deposition and oral absorption of the swallowed dose. When administered orally, in healthy male volunteers, the bioavailability of BDP is negligible but pre-systemic conversion to B-17-MP results in 41% (95% CI 27- 62 %) of the dose being available as B-17-MP.
Metabolism
BDP is cleared very rapidly from the systemic circulation, owing to extensive first pass metabolism. The main product of metabolism is the active metabolite (B-17-MP). Minor inactive metabolites, Rinoclenil-21-monopropionate (B-21-MP) and Rinoclenil (BOH), are also formed but these contribute little to systemic exposure.
Distribution
The tissue distribution at steady state for BDP is moderate (20L) but more extensive for B-17-MP (424L). Plasma protein binding is moderately high (87%).
Elimination
The elimination of BDP and B-17-MP are characterised by high plasma clearance (150 and 120L/h) with corresponding terminal elimination half lives of 0.5h and 2.7h. Following oral administration of tritiated BDP, approximately 60% of the dose was excreted in the faeces within 96 hours mainly as free and conjugated polar metabolites. Approximately 12% of the dose was excreted as free and conjugated polar metabolites in the urine.
Patients should be instructed in the proper use of the inhaler, and their technique checked, to ensure that the drug reaches the target areas within the lungs. They should also be made aware that Easyhaler® Rinoclenil 200 micrograms/dose has to be used regularly every day for optimum benefit. Patients should be made aware of the prophylactic nature of therapy with Easyhaler® Rinoclenil 200 micrograms/dose and that they should be used regularly, even when they are asymptomatic.
Easyhaler® Rinoclenil 200 micrograms/dose is not designed to relieve acute asthma symptoms for which an inhaled short-acting bronchodilator is required. Patients should be advised to have such rescue medication available.
Severe asthma requires regular medical assessment, including lung-function testing, as patients are at risk of severe attacks and even death.
Increasing use of bronchodilators, in particular short-acting inhaled beta2 agonists to relieve symptoms indicates deterioration of asthma control. If patients find that short acting relief bronchodilator treatment becomes less effective or they need more inhalations than usual, medical attention must be sought.
In this situation, patients should be reassessed and consideration given to the need for increased anti-inflammatory therapy (e.g. higher doses of inhaled corticosteroid or a course of oral corticosteroid) considered. Severe exacerbations of asthma must be treated in the normal way.
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is important therefore that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.
It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.
Prolonged treatment with high doses of inhaled corticosteroids, particularly higher than recommended doses, may result in clinically significant adrenal suppression. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
Lack of response or severe exacerbations of asthma should be treated by increasing the dose of inhaled Rinoclenil dipropionate and, if necessary, by giving a systemic steroid and/or antibiotic if there is an infection, and by use of beta-agonist therapy.
For the transfer of patients being treated with oral corticosteroids:
The transfer of oral steroid-dependent patients to Easyhaler® Rinoclenil 200 micrograms/dose and their subsequent management needs special care as recovery from impaired adrenocortical function, caused by prolonged systemic steroid therapy, may take a considerable time.
Patients who have been treated with systemic steroids for long periods of time or at a high dose may have adrenocortical suppression. With these patients adrenocortical function should be monitored regularly and their dose of systemic steroid reduced cautiously.
After approximately a week, gradual withdrawal of the systemic steroid is commenced. Decrements in dosages should be appropriate to the level of maintenance systemic steroid, and introduced at not less than weekly intervals. For maintenance doses of prednisolone (or equivalent) of 10mg daily or less, the decrements in dose should not be greater than 1mg per day, at not less than weekly intervals. For maintenance doses of prednisolone in excess of 10mg daily, it may be appropriate to employ cautiously, larger decrements in dose at weekly intervals.
Some patients feel unwell in a non-specific way during the withdrawal phase despite maintenance or even improvement of the respiratory function. They should be encouraged to persevere with Easyhaler® Rinoclenil 200 micrograms/dose and withdrawal of systemic steroid continued, unless there are objective signs of adrenal insufficiency.
Patients weaned off oral steroids whose adrenocortical function is impaired should carry a steroid warning card indicating that they may need supplementary systemic steroid during periods of stress, e.g. worsening asthma attacks, chest infections, major intercurrent illness, surgery, trauma, etc.
Replacement of systemic steroid treatment with inhaled therapy sometimes unmasks allergies such as allergic rhinitis or eczema previously controlled by the systemic drug. These allergies should be symptomatically treated with antihistamine and/or topical preparations, including topical steroids.
Treatment with Easyhaler® Rinoclenil 200 micrograms/dose should not be stopped abruptly.
As with all inhaled corticosteroids, special care is necessary in patients with active or quiescent pulmonary tuberculosis.
Easyhaler® Rinoclenil contains approximately 7mg of lactose per dose. This amount does not normally cause problems in lactose intolerant people. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose galactose malabsorption should not take this medicine.
No adverse effect has been reported.
Easyhaler® Rinoclenil 200 micrograms/dose is for oral inhalation use only.
Patients should be made aware of the prophylactic nature of therapy with inhaled Rinoclenil dipropionate and that it should be taken regularly everyday even when they are asymptomatic.
Patients should be given a starting dose of inhaled Rinoclenil dipropionate appropriate to the severity of their disease. The dose may then be adjusted until control is achieved and should be titrated to the lowest dose at which effective control of asthma is maintained.
Adults
The usual starting dose is 200 micrograms twice a day. In more severe cases the starting dose may need to increase to 600 to 800 micrograms per day which may then be reduced when the patient's asthma has stabilised. The total daily dose may be administered as two, three, or four divided doses.
Paediatric population
Easyhaler® Rinoclenil 200 micrograms/dose is not recommended for children.
Special Patient Groups
There is no need to adjust the dose in older people or in those with hepatic or renal impairment.
Patients have to be instructed to perform a rapid and forced inhalation through the Easyhaler device. Patients have to be instructed not to exhale into the device. Illustrated user's instructions for use accompany each package.
